По алфавиту
J A Hank, J E Surfus, J Gan, P Jaeger, S D Gillies, R A Reisfeld, P M Sondel
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2)Clin Cancer Res. 1996 Dec;2(12):1951-9.
J Atzpodien, E Lopez Hänninen, H Kirchner, H Bodenstein, M Pfreundschuh, U Rebmann, B Metzner, H J Illiger, G Jakse, T Niesel, et al.
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinomaJ Clin Oncol. 1995 Feb;13(2):497-501.
J Atzpodien, H Kirchner, A Körfer, M Hadam, A Schomburg, T Menzel, M Deckert, A Franzke, M Volkenandt, I Dallmann, et al.
Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2Tumour Biol. 1993;14(6):354-9.
J Atzpodien, H Kirchner, H Poliwoda
[Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma]Med Klin (Munich). 1996 Apr 12;91 Suppl 3:38-43.
J Atzpodien, H Kirchner, U Jonas, L Bergmann, H Schott, H Heynemann, P Fornara, S A Loening, J Roigas, S C Müller, H Bodenstein, S Pomer, B Metzner, U Rebmann, R Oberneder, M Siebels, T Wandert, T Puchberger, M Reitz, Prospectively Randomized Trial of the
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Clin Oncol. 2004 Apr 1;22(7):1188-94.
J Atzpodien, H Kirchner, U Rebmann, M Soder, U Gertenbach, M Siebels, J Roigas, R Raschke, S Salm, B Schwindl, S C Müller, S Hauser, C Leiber, E Huland, H Heinzer, S Siemer, B Metzner, H Heynemann, P Fornara, M Reitz
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)Br J Cancer. 2006 Aug 21;95(4):463-9.
J Atzpodien, H Poliwoda, H Kirchner
alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patientsSemin Oncol. 1991 Oct;18(5 Suppl 7):108-12.
J C Yang, S A Rosenberg
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancerCancer J Sci Am. 1997 Dec;3 Suppl 1:S79-84.
J C Yang, S L Topalian, D J Schwartzentruber, D R Parkinson, F M Marincola, J S Weber, C A Seipp, D E White, S A Rosenberg
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2Cancer. 1995 Aug 15;76(4):687-94.
J E Cortes, H M Kantarjian, S O’Brien, F Giles, M J Keating, E J Freireich, E H Estey
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remissionCancer. 1999 Apr 1;85(7):1506-13.
J M Tourani, V Levy, J Briere, R Levy, C Franks, J M Andrieu
Interleukin-2 therapy for refractory and relapsing lymphomasEur J Cancer. 1991;27(12):1676-80.
J P Dutcher, M Atkins, R Fisher, G Weiss, K Margolin, F Aronson, J Sosman, M Lotze, M Gordon, T Logan, J Mier
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8.
J S Miller, J Tessmer-Tuck, B A Pierson, D Weisdorf, P McGlave, B R Blazar, E Katsanis, C Verfaillie, J Lebkowski, J Radford Jr, L J Burns
Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activityBiol Blood Marrow Transplant. 1997 Apr;3(1):34-44.
Jakub Tomala, Helena Chmelova, Jiri Strohalm, Karel Ulbrich, Milada Sirova, Blanka Rihova, Marek Kovar
Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activityInt J Cancer. 2011 Oct 15;129(8):2002-12.
Jakub Tomala, Helena Chmelova, Tomas Mrkvan, Blanka Rihova, Marek Kovar
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapyJ Immunol. 2009 Oct 15;183(8):4904-12.
Jakub Tomala, Jirina Kovarova, Martina Kabesova, Petra Votavova, Helena Chmelova, Barbora Dvorakova, Blanka Rihova, Marek Kovar
Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionallyACS Chem Biol. 2013 May 17;8(5):871-6.
Jakub Tomala, Marek Kovar
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?Oncoimmunology. 2015 Nov 3;5(3):e1102829.
Jamal Majidpoora, Keywan Mortezaee.
International Immunopharmacology. — 2021. — Volume 98, September, 107836.
James C Yang, Richard M Sherry, Seth M Steinberg, Suzanne L Topalian, Douglas J Schwartzentruber, Patrick Hwu, Claudia A Seipp, Linda Rogers-Freezer, Kathleen E Morton, Donald E White, David J Liewehr, Maria J Merino, Steven A Rosenberg
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancerJ Clin Oncol. 2003 Aug 15;21(16):3127-32.
Janice P Dutcher
Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanomaOncology (Williston Park). 2002 Nov;16(11 Suppl 13):4-10.
Jared E Lopes, Jan L Fisher, Heather L Flick, Chunhua Wang, Lei Sun, Marc S Ernstoff, Juan C Alvarez, Heather C Losey
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapyJ Immunother Cancer. 2020 Apr;8(1):e000673.
Jens Atzpodien, Reinhard Hoffmann, Marcus Franzke, Christian Stief, Thomas Wandert, Martina Reitz
Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinomaCancer. 2002 Sep 1;95(5):1045-50.
Jessie Gills, William P. Parker, Scott Pate et al.
The Role of High Dose Interleukin-2 in the Era of Targeted Therapy.https://doi.org/10.1016/j.juro.2017.03.076 American Urological Association Education and Research, Inc.Volume 198. Issue 3. September 2017. Page: 538-545.
Jia-Yuan Zhang, Fiona Hamey, Dominik Trzupek et al.
www.medrxiv.org
Jin P., Wang E., Provenzano M., Stroncek D., Marincola F.M.
Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy.Crit Rev Immunol. 2007;27(5):437-48.
Jing He, Ruijun Zhang, Miao Shao et al.
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.Реестр клинических исследований США. 1 апреля 2023 г.
Jing He, Xia Zhang, Yunbo Wei et al.
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosusNat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8. PMID: 27500725.
Jost L.M., Stahel R.A.
Interleukin-2 as single agent.The role of interleukin-2 in the treatment of cancer patients. Springer, Dordrecht. -Pp 7-28. — https://doi.org/10.1007/978-94-011-1753-1_2.
Junming Xian, Huan Yang, Yinghe Lin, Shixi Liu
Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinomaArch Otolaryngol Head Neck Surg. 2005 Dec;131(12):1079-85.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.